XML 55 R44.htm IDEA: XBRL DOCUMENT
v3.25.2

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Schedule of Research and Development Expense [Line Items] |  |  |  |
Research and development | $ 2,580 | $ 2,899 | $ 4,837 | $ 5,594
Research |  |  |  |
Schedule of Research and Development Expense [Line Items] |  |  |  |
Research and development | 291 | 336 | 605 | 720
Drug Development |  |  |  |
Schedule of Research and Development Expense [Line Items] |  |  |  |
Research and development | 1,095 | 1,096 | 2,176 | 2,180
Other |  |  |  |
Schedule of Research and Development Expense [Line Items] |  |  |  |
Research and development | $ 1,195 | $ 1,467 | $ 2,057 | $ 2,695

X
- Definition Schedule of Research and Development Expense + References No definition available. + Details
Name: | bmy_ScheduleOfResearchAndDevelopmentExpenseLineItems
Namespace Prefix: | bmy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_NatureOfExpenseAxis=bmy_OtherResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_NatureOfExpenseAxis=bmy_DrugDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_NatureOfExpenseAxis=bmy_ResearchAndDevelopmentExpenseOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |